Purple Biotech Ltd. American Depositary Shares (PPBT)

FairStock Score: 14/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earning power, honest numbers, and a margin of safety. Purple Biotech is not that kind of business. It is a clinical-stage oncology company with about 10 employees, two experimental programs, and no meaningful commercial revenue disclosed. At the close on 2026-10-13, the shares were $1.36, giving a $7.0 million market cap. FairStock's calculations show a P/B of 0.11 and a negative P/E of -0.03. The low P/B might attract a Graham-style screen, but book value in a cash-burning biotech is not the same as a bargain in a stable industrial. The cash flow is the problem. Trailing-twelve-month free cash flow was -$7.8 million, which is larger than the entire market cap, producing a FairStock FCF yield of -111.3%. Debt is minimal—D/E 0.01—but negative ROE of -111.13% and ROCE of -20.31% show that capital is being consumed, not compounded. FairStock's Piotroski score is 3/9, and the Altman Z-Score of -14.32 points to severe financial distress. The Lynch category is none because there are only 0 years of filed results, against the required 3, so there is no track record to classify. The 52-week range of $1.16 to $14.10 shows how violently sentiment has swung, and a beta of -0.53 does not make the underlying science safer. Growth depends on CM24 in Phase 2 for pancreatic ductal adenocarcinoma and NT219. Those are binary events. I would not call this cheap on the numbers; it is a speculative option on trial data, not a value investment.

In plain English: Purple Biotech is a very small cancer-drug developer with about 10 employees. It has no steady sales, loses money, and burns more cash than its entire market value each year. At $1.36, the price looks low on some measures, but the business looks weak and depends on risky clinical trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer